Patient-derived-organoid Drug Sensitivity Screening and its Consistency with Clinical Efficacy of Pan-cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063320

Enrollment

Unknown

Registered

2022-09-04

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumor

Interventions

Case Series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with malignant tumor by pathology; 2. No gender restriction, age >= 18 years old; 3. Tumor samples are sufficient for in vitro culture after pathological diagnosis or gene sequencing; 4. Be able to understand the content of the informed consent form, sign the informed consent form, and be willing to cooperate with relevant follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or Lactating; 2. Patients who are participating in other mutually exclusive studies; 3. Other conditions that are not suitable for study participation.

Design outcomes

Primary

Measure	Time frame
Area under the curve of drug-response curve;Objective Response Rate;	—

Countries

China

Contacts

Public ContactLinlin Lu

Qingdao Central Hospital

lulinlin2007@163.com+86 18515216669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026